Abstract
Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.
| Original language | English |
|---|---|
| Journal | Neurological Sciences |
| Volume | 27 |
| Issue number | SUPPL. 2 |
| DOIs | |
| Publication status | Published - Sep 2006 |
Fingerprint
Keywords
- Clinical trial
- Migraine
- Open-label extension phase
- Pooled analysis
- Prophylaxis
- Topiramate
ASJC Scopus subject areas
- Neuroscience(all)
- Clinical Neurology
Cite this
Topiramate in migraine prophylaxis : Data from a pooled analysis and open-label extension study. / Bussone, G.; Usai, S.; D'Amico, D.
In: Neurological Sciences, Vol. 27, No. SUPPL. 2, 09.2006.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Topiramate in migraine prophylaxis
T2 - Data from a pooled analysis and open-label extension study
AU - Bussone, G.
AU - Usai, S.
AU - D'Amico, D.
PY - 2006/9
Y1 - 2006/9
N2 - Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.
AB - Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.
KW - Clinical trial
KW - Migraine
KW - Open-label extension phase
KW - Pooled analysis
KW - Prophylaxis
KW - Topiramate
UR - http://www.scopus.com/inward/record.url?scp=33746269166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746269166&partnerID=8YFLogxK
U2 - 10.1007/s10072-006-0593-z
DO - 10.1007/s10072-006-0593-z
M3 - Article
C2 - 16688622
AN - SCOPUS:33746269166
VL - 27
JO - Neurological Sciences
JF - Neurological Sciences
SN - 1590-1874
IS - SUPPL. 2
ER -